Brief: BioInvent Presents Promising Early Data in CTCL
08/12/2025 07:51
Dec 8 (Reuters) - BioInvent International AB BINV.ST: SAID ON SUNDAY PRESENTS PROMISING EARLY PHASE 2A BI-1808 MONOTHERAPY DATA IN CTCL AT ASH 2025 92% DISEASE CONTROL RATE IN RELAPSED/REFRACTORY CTCL OVERALL, TREATMENT HAS BEEN WELL-TOLERATED WITH ENCOURAGING MONOTHERAPY ACTIVITY IN PATIENTS WITH CTCL Source text for Workspace: ID:nNDL9XLbFS Further company coverage: BINV.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))